our generate continue and we our and cash flow Vivek, results financials, afternoon, of good execute everyone. strong Thanks, toward breakeven. Across objective to
expenses are Continued realizing leverage expansion progress. from to the while profit, driving again our operating gross
sold either revenue $XX.X the during year out to as expect the or this posted North dynamic line, incurred, quarter outperformance XX% quarter. in to sales of third representing We products the top of operationally. costs product XXXX relative America we close led growth We by year-over-year continue with on million, for
and Foreign exchange X% top than line in was expected on resulted pressure more headwind previously the we a impactful line top year-over-year.
growing good growth our led rates other largest year-over-year. sales headwind center U.S. year-over-year has mentioned, the impacting the U.S. by to U.S. in their for U.S. basis U.S. to customers of customer previously a a XX% EMEA, upon with euro, majority the As and platelet continued the the strength been This based portion base in XX% continued this into where customers XXXX are XXXX today. INTERCEPT impacted comparable well growth such, us of quarter blood sales In dollar likely and is be negatively our as was across on as dollars. reported growing dollar year-over-year
XXXX providing at [XXX] we're of U.S. it that XXXX, rate call, beginning While dollar around worth euro, was is the today's not on [ph]. for the mentioning guidance
further product neighborhood be even million. revenue dollar in could full-year our impacted So, without we XXXX negatively of the anticipate $X strengthening,
New revenues the the continue persist this XXXX, FX months several the with impact into first expect we for see negatively to product to dynamic Year. Additionally, in during potential to
in Our XX% third increase internationally. and On in by year-over-year of U.S. platelet treatable XX% year-to-date the U.S. doses the has of quarter grown year-over-year and internationally. in XX% growth reflected increase the number calculated number doses XX% basis, a a the
quarter, In mix product of for the INTERCEPT terms our over disposable QX sales of product represented XX% revenue. of kits
million revenue period. contract million government our totaled guidance, product in the and our prior in to included addition not $X revenue In QX year versus from $X.X
on be Defense a blood recent blood LyoCryo, whole this BARDA IFC line our U.S. will the non-frozen Department with supported red work the cells, award to of lyophilized initiative FDA, from on the formulation and by which over recognized in addition the the contracts for detail Obi the In based with in milestone DoD contract, next more two will years. the from differs his and bill we the closing The is have as comments. LyoCryo FDA. BARDA with that contract incurred a discuss of
to now Turning product gross gross profit and our margins.
was $XX.X of gross million during basis profit gross period, when points over the year-over-year. year product XX% prior million, compared an and XXX quarter year increase to increased XX.X%, XXX for to quarter third was Our sequentially. compared period the $XX.X prior the Product points basis which improved margin
last beneficial to discussed the that with COGS dollar quarter, denominated in our we U.S. of for gross majority strengthening actually As are sales of products euros, dollars denominated. particularly the U.S. our margins,
totaled $XX.X included million, and period Moving in million operating on, million, year. expenses based the $XX.X year stock with our roughly $XX.X totaled R&D prior compared third in-line type, expense By to third non-cash $X.X specific quarter quarter expense million during compensation. the prior
million, quarter in million year Third was SG&A period. to $XX.X the $XX.X prior compared expense
and headlines, leverage, immune higher our invest business and the that While is make while on to the is driving we to execution business financial deliver us costs. not our focus, operating inflationary to sustained discipline in these commitment, pressures allowing absorb continue
$X.XX share, loss the XXXX, Net Cerus line, narrowed to Cerus $X.X attributable year bottom totaled million to compared $XX.X for compared net to million for attributable period. same XX, three months the diluted for September million to in $X.X per or share XXXX. On the or the QX ended $X.XX XX% by diluted prior period or when loss reported per
XXXX to a half to less Our during ago a as third a where they XXXX. quarter Year $XX.X year two-thirds lower reported adjusted for million, the were of losses than million, year $X.X to adjusted date were prior to negative months a date compared by first than XXXX. losses were year of negative our to totaled $X.X figure negative $X.X the EBITDA to non-GAAP and totaling nine million our date of million third quarter with compared the the as negative EBITDA to non-GAAP a almost total reported by
this We pleased front are on stated progress reaching cash with goal as approach we our flow of our breakeven.
cash position the balance We to cash strong and Turning equivalents quarter million third and cash of a sheet flows. the on in with sheet. ended cash $XXX.X the balance
would remaining terms my to the less in around used wrap-up the compared of expect year the update feel revenues in of we cash during that year. $XXX period. end XXXX, cash our XXXX to good With finish our prior $XXX two revenue to $X.X was to today, million months demand million I the product In product full-year To be operations million, guidance. utilization, have commentary products from market $X.X with like now the of for we our into balance visibility We million. in range than
to However, of the year. much served top consistent a line the the meaningful have impact for of the of realities U.S. headwind dollar strong as the and
we robust impacting as growth stronger out $X end up by million. As a could finish our new that reinforces underlying reported our the I approximately mentioned With previously, the said, year. negatively of XXXX revenues we business product dollar the expect guidance
in combined to improved measured continue confident about EBITDA Obi. expected with the non-GAAP by feel call operating me QX turn gross that, our expense as the cash flow And the we year-over-year back our ability with growth to let revenues, over leverage, adjusted and to With breakeven margins realize metric.
